157 related articles for article (PubMed ID: 33474593)
1. Homology modeling and molecular docking simulation of some novel imidazo[1,2-a]pyridine-3-carboxamide (IPA) series as inhibitors of Mycobacterium tuberculosis.
Abdullahi M; Adeniji SE; Arthur DE; Haruna A
J Genet Eng Biotechnol; 2021 Jan; 19(1):12. PubMed ID: 33474593
[TBL] [Abstract][Full Text] [Related]
2. In-silico design and ADMET predictions of some new imidazo[1,2-a]pyridine-3-carboxamides (IPAs) as anti-tubercular agents.
Abdullahi M; Das N; Adeniji SE; Usman AK; Sani AM
J Clin Tuberc Other Mycobact Dis; 2021 Dec; 25():100276. PubMed ID: 34568589
[TBL] [Abstract][Full Text] [Related]
3. Refined homology model of cytochrome bcc complex B subunit for virtual screening of potential anti-tuberculosis agents.
Pan Z; Wang Y; Gu X; Wang J; Cheng M
J Biomol Struct Dyn; 2020 Oct; 38(16):4733-4745. PubMed ID: 31674290
[TBL] [Abstract][Full Text] [Related]
4. Telacebec (Q203): Is there a novel effective and safe anti-tuberculosis drug on the horizon?
Malík I; Čižmárik J; Kováč G; Pecháčová M; Hudecova L
Ceska Slov Farm; 2021; 70(5):164–171. PubMed ID: 34875838
[TBL] [Abstract][Full Text] [Related]
5. Telacebec (Q203): Is there a novel effective and safe anti-tuberculosis drug on the horizon?
Malík I; Čižmárik J; Kováč G; Pecháčová M; Hudecova L
Ceska Slov Farm; 2021; 70(5):164-171. PubMed ID: 35114793
[TBL] [Abstract][Full Text] [Related]
6. Ursolic acid as a potential inhibitor of Mycobacterium tuberculosis cytochrome bc1 oxidase-a molecular modelling perspective.
Tembe N; Machaba KE; Ndagi U; Kumalo HM; Mhlongo NN
J Mol Model; 2022 Jan; 28(2):35. PubMed ID: 35022913
[TBL] [Abstract][Full Text] [Related]
7. Identification of 4-Amino-Thieno[2,3-
Harrison GA; Mayer Bridwell AE; Singh M; Jayaraman K; Weiss LA; Kinsella RL; Aneke JS; Flentie K; Schene ME; Gaggioli M; Solomon SD; Wildman SA; Meyers MJ; Stallings CL
mSphere; 2019 Sep; 4(5):. PubMed ID: 31511370
[TBL] [Abstract][Full Text] [Related]
8. Investigation of protein-ligand binding motions through protein conformational morphing and clustering of cytochrome bc1-aa3 super complex.
Sindhu T; Rajamanikandan S; Jeyakanthan J; Pal D
J Mol Graph Model; 2023 Jan; 118():108347. PubMed ID: 36208591
[TBL] [Abstract][Full Text] [Related]
9. Identification of new benzamide inhibitor against α-subunit of tryptophan synthase from Mycobacterium tuberculosis through structure-based virtual screening, anti-tuberculosis activity and molecular dynamics simulations.
Naz S; Farooq U; Ali S; Sarwar R; Khan S; Abagyan R
J Biomol Struct Dyn; 2019 Mar; 37(4):1043-1053. PubMed ID: 29502488
[TBL] [Abstract][Full Text] [Related]
10. Arrival of Imidazo[2,1-b]thiazole-5-carboxamides: Potent Anti-tuberculosis Agents That Target QcrB.
Moraski GC; Seeger N; Miller PA; Oliver AG; Boshoff HI; Cho S; Mulugeta S; Anderson JR; Franzblau SG; Miller MJ
ACS Infect Dis; 2016 Jun; 2(6):393-8. PubMed ID: 27627627
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.
Lokesh BVS; Prasad YR; Shaik AB
Infect Disord Drug Targets; 2019; 19(3):310-321. PubMed ID: 30556506
[TBL] [Abstract][Full Text] [Related]
12. Pyrazolo[1,5- a]pyridine Inhibitor of the Respiratory Cytochrome bcc Complex for the Treatment of Drug-Resistant Tuberculosis.
Lu X; Williams Z; Hards K; Tang J; Cheung CY; Aung HL; Wang B; Liu Z; Hu X; Lenaerts A; Woolhiser L; Hastings C; Zhang X; Wang Z; Rhee K; Ding K; Zhang T; Cook GM
ACS Infect Dis; 2019 Feb; 5(2):239-249. PubMed ID: 30485737
[TBL] [Abstract][Full Text] [Related]
13. Benzothiazole analogs as potential anti-TB agents: computational input and molecular dynamics.
Venugopala KN; Khedr MA; Pillay M; Nayak SK; Chandrashekharappa S; Aldhubiab BE; Harsha S; Attimard M; Odhav B
J Biomol Struct Dyn; 2019 Apr; 37(7):1830-1842. PubMed ID: 29697293
[TBL] [Abstract][Full Text] [Related]
14. Advancement of Imidazo[1,2-
Moraski GC; Markley LD; Cramer J; Hipskind PA; Boshoff H; Bailey M; Alling T; Ollinger J; Parish T; Miller MJ
ACS Med Chem Lett; 2013 Jul; 4(7):675-679. PubMed ID: 23930153
[TBL] [Abstract][Full Text] [Related]
15. Drug discovery in tuberculosis. New drug targets and antimycobacterial agents.
Campaniço A; Moreira R; Lopes F
Eur J Med Chem; 2018 Apr; 150():525-545. PubMed ID: 29549838
[TBL] [Abstract][Full Text] [Related]
16. An integrated computational approach of molecular dynamics simulations, receptor binding studies and pharmacophore mapping analysis in search of potent inhibitors against tuberculosis.
Agarwal S; Verma E; Kumar V; Lall N; Sau S; Iyer AK; Kashaw SK
J Mol Graph Model; 2018 Aug; 83():17-32. PubMed ID: 29753941
[TBL] [Abstract][Full Text] [Related]
17. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of (-)-deoxypergularinine, on its own and in combination with anti-tubercular drugs, against resistant strains of Mycobacterium tuberculosis.
Nam KW; Jang WS; Jyoti MA; Kim S; Lee BE; Song HY
Phytomedicine; 2016 May; 23(5):578-82. PubMed ID: 27064017
[TBL] [Abstract][Full Text] [Related]
19. Docking studies on novel alkaloid tryptanthrin and its analogues against enoyl-acyl carrier protein reductase (InhA) of Mycobacterium tuberculosis.
Tripathi A; Wadia N; Bindal D; Jana T
Indian J Biochem Biophys; 2012 Dec; 49(6):435-41. PubMed ID: 23350278
[TBL] [Abstract][Full Text] [Related]
20.
Jagadeb M; Rath SN; Sonawane A
J Biomol Struct Dyn; 2019 Aug; 37(13):3388-3398. PubMed ID: 30132739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
